{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:14:08Z","timestamp":1787354048731,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K06427"],"award-info":[{"award-number":["23K06427"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02326-4","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T19:34:51Z","timestamp":1781465691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Highly CD81-expressing stromal cells characterize a tumor-suppressive immune microenvironment in invasive breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Kenju","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Naiki-Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"issue":"4","key":"2326_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"issue":"3","key":"2326_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"8","key":"2326_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D Ohlund","year":"2014","unstructured":"Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211(8):1503\u201323.","journal-title":"J Exp Med"},{"issue":"1","key":"2326_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"issue":"2","key":"2326_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1541-7786.MCR-21-0282","volume":"20","author":"T Simon","year":"2022","unstructured":"Simon T, Salhia B. Cancer-associated fibroblast subpopulations with diverse and dynamic roles in the tumor microenvironment. Mol Cancer Res. 2022;20(2):183\u201392.","journal-title":"Mol Cancer Res"},{"key":"2326_CR6","doi-asserted-by":"publisher","first-page":"110601","DOI":"10.1016\/j.intimp.2023.110601","volume":"122","author":"S Guo","year":"2023","unstructured":"Guo S, et al. Cancer-associated fibroblasts: Just on the opposite side of antitumour immunity? Int Immunopharmacol. 2023;122:110601.","journal-title":"Int Immunopharmacol"},{"issue":"24","key":"2326_CR7","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1111\/bph.12260","volume":"171","author":"S Detchokul","year":"2014","unstructured":"Detchokul S, et al. Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol. 2014;171(24):5462\u201390.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2326_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13578-023-00995-8","volume":"13","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, et al. The versatile roles of testrapanins in cancer from intracellular signaling to cell-cell communication: cell membrane proteins without ligands. Cell Biosci. 2023;13(1):59.","journal-title":"Cell Biosci"},{"issue":"7","key":"2326_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.20190186","volume":"216","author":"F Vences-Catalan","year":"2019","unstructured":"Vences-Catalan F, et al. CD81 is a novel immunotherapeutic target for B cell lymphoma. J Exp Med. 2019;216(7):1497\u2013508.","journal-title":"J Exp Med"},{"issue":"22","key":"2326_CR10","doi-asserted-by":"publisher","first-page":"15691","DOI":"10.1074\/jbc.M113.534206","volume":"289","author":"IK Hong","year":"2014","unstructured":"Hong IK, et al. The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem. 2014;289(22):15691\u2013704.","journal-title":"J Biol Chem"},{"issue":"21","key":"2326_CR11","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/0008-5472.CAN-15-1021","volume":"75","author":"F Vences-Catalan","year":"2015","unstructured":"Vences-Catalan F, et al. Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res. 2015;75(21):4517\u201326.","journal-title":"Cancer Res"},{"key":"2326_CR12","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.12659\/MSM.911612","volume":"24","author":"N Zhang","year":"2018","unstructured":"Zhang N, et al. Increased expression of cd81 in breast cancer tissue is associated with reduced patient prognosis and increased cell migration and proliferation in MDA-MB-231 and MDA-MB-435S human breast cancer cell lines in vitro. Med Sci Monit. 2018;24:5739\u201347.","journal-title":"Med Sci Monit"},{"issue":"1","key":"2326_CR13","first-page":"755","volume":"19","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in vitro. Exp Ther Med. 2020;19(1):755\u201361.","journal-title":"Exp Ther Med"},{"issue":"1","key":"2326_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21873\/anticanres.16130","volume":"43","author":"N FUJII","year":"2023","unstructured":"FUJII N, et al. CD9-positive exosomes derived from cancer-associated fibroblasts might inhibit the proliferation of malignant melanoma cells. Anticancer Res. 2023;43(1):25\u201333.","journal-title":"Anticancer Res"},{"issue":"2","key":"2326_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cei\/uxab039","volume":"207","author":"A Gowhari Shabgah","year":"2022","unstructured":"Gowhari Shabgah A, et al. Does CCL19 act as a double-edged sword in cancer development? Clin Exp Immunol. 2022;207(2):164\u201375.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2326_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaci.2017.12.998","volume":"142","author":"HW Cheng","year":"2018","unstructured":"Cheng HW, et al. CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses. J Allergy Clin Immunol. 2018;142(4):1257\u2013e12714.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2326_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cell.2024.10.042","volume":"188","author":"L Onder","year":"2025","unstructured":"Onder L, et al. Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell. 2025;188(2):430\u2013e44620.","journal-title":"Cell"},{"issue":"11","key":"2326_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3298","volume":"12","author":"JP Girard","year":"2012","unstructured":"Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12(11):762\u201373.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2326_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.trecan.2020.10.001","volume":"7","author":"S Milutinovic","year":"2021","unstructured":"Milutinovic S, et al. The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer. 2021;7(3):214\u201325.","journal-title":"Trends Cancer"},{"issue":"3","key":"2326_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2023.02.002","volume":"41","author":"G Vella","year":"2023","unstructured":"Vella G, Hua Y, Bergers G. High endothelial venules in cancer: Regulation, function, and therapeutic implication. Cancer Cell. 2023;41(3):527\u201345.","journal-title":"Cancer Cell"},{"issue":"6","key":"2326_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4161\/onci.20492","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet L, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1(6):829\u201339.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2326_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-21-0369","volume":"10","author":"J Sawada","year":"2022","unstructured":"Sawada J, et al. Molecular signature of tumor-associated high endothelial venules that can predict breast cancer survival. Cancer Immunol Res. 2022;10(4):468\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2326_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir A, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40(3):318\u2013e3349.","journal-title":"Cancer Cell"},{"issue":"12","key":"2326_CR24","doi-asserted-by":"publisher","first-page":"e13513","DOI":"10.1111\/cpr.13513","volume":"56","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, et al. High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma. Cell Prolif. 2023;56(12):e13513.","journal-title":"Cell Prolif"},{"issue":"W1","key":"2326_CR25","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566\u201370.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2326_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2326_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2326_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40364-020-00245-w","volume":"8","author":"C Han","year":"2020","unstructured":"Han C, Liu T, Yin R. Biomarkers for cancer-associated fibroblasts. Biomark Res. 2020;8(1):64.","journal-title":"Biomark Res"},{"issue":"8","key":"2326_CR29","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1111\/cas.14537","volume":"111","author":"R Kanzaki","year":"2020","unstructured":"Kanzaki R, Pietras K. Heterogeneity of cancer-associated fibroblasts: opportunities for precision medicine. Cancer Sci. 2020;111(8):2708\u201317.","journal-title":"Cancer Sci"},{"issue":"5","key":"2326_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cac2.12291","volume":"42","author":"D Hu","year":"2022","unstructured":"Hu D, et al. Cancer-associated fibroblasts in breast cancer: challenges and opportunities. Cancer Commun (Lond). 2022;42(5):401\u201334.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"2326_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41(3):434\u201349.","journal-title":"Cancer Cell"},{"issue":"1","key":"2326_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12964-023-01125-0","volume":"21","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, et al. What is new in cancer-associated fibroblast biomarkers? Cell Commun Signal. 2023;21(1):96.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"2326_CR33","doi-asserted-by":"publisher","first-page":"e13592","DOI":"10.1111\/cpr.13592","volume":"57","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity: single vision for heterogeneous environment. Cell Prolif. 2024;57(5):e13592.","journal-title":"Cell Prolif"},{"issue":"4","key":"2326_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s13402-024-00931-z","volume":"47","author":"D Coursier","year":"2024","unstructured":"Coursier D, Calvo F. CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance. Cell Oncol (Dordr). 2024;47(4):1091\u2013112.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2326_CR35","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","volume":"9","author":"M Bartoschek","year":"2018","unstructured":"Bartoschek M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):5150.","journal-title":"Nat Commun"},{"issue":"1","key":"2326_CR36","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","volume":"14","author":"L Cords","year":"2023","unstructured":"Cords L, et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat Commun. 2023;14(1):4294.","journal-title":"Nat Commun"},{"issue":"8","key":"2326_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"7","key":"2326_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, et al. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793\u2013807.","journal-title":"Nat Cancer"},{"key":"2326_CR39","doi-asserted-by":"crossref","unstructured":"Miyai Y et al. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Sci Alliance. 2022;5(6).","DOI":"10.26508\/lsa.202101230"},{"issue":"1","key":"2326_CR40","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1038\/s41598-023-33282-0","volume":"13","author":"M Wishahi","year":"2023","unstructured":"Wishahi M, et al. Telocytes and ezrin expression in normal-appearing tissues adjacent to urothelial bladder carcinoma as predictors of invasiveness and recurrence. Sci Rep. 2023;13(1):6179.","journal-title":"Sci Rep"},{"key":"2326_CR41","doi-asserted-by":"crossref","unstructured":"Oksel N et al. Evaluation of immunophenotypic characteristics and quantitative differences of telocytes between invasive breast cancer subtypes. Life (Basel). 2025; 15(7).","DOI":"10.3390\/life15071040"},{"issue":"1","key":"2326_CR42","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1038\/s41598-020-64523-1","volume":"10","author":"Q Liang","year":"2020","unstructured":"Liang Q, et al. Effect of Ki-67 Expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648.","journal-title":"Sci Rep"},{"key":"2326_CR43","first-page":"117","volume":"16","author":"Q Ma","year":"2024","unstructured":"Ma Q, et al. The role of Ki-67 in HR+\/HER2- breast cancer: a real-world study of 956 patients. Breast Cancer (Dove Med Press). 2024;16:117\u201326.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2326_CR44","doi-asserted-by":"crossref","unstructured":"Kurbel S. Dependence of Ki-67 values on tumor size in 1040 breast cancers of five immunohistochemical phenotypes: an argument for a minority of invasive breast cancers with high mitotic rates of a little dependence on er and her2 expressions. Int J Clin Stud Med Case Rep. 2024;35(1).","DOI":"10.46998\/IJCMCR.2023.35.000852"},{"key":"2326_CR45","doi-asserted-by":"crossref","unstructured":"Suzuki H, Kaneko MK, Kato Y. Roles podoplanin malignant progression tumor. cells. 2022;11(3):575.","DOI":"10.3390\/cells11030575"},{"key":"2326_CR46","doi-asserted-by":"publisher","first-page":"1507371","DOI":"10.3389\/fimmu.2024.1507371","volume":"15","author":"F Boissiere-Michot","year":"2024","unstructured":"Boissiere-Michot F, et al. Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol. 2024;15:1507371.","journal-title":"Front Immunol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02326-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:02:20Z","timestamp":1787324540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2326"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02326-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of the Nagoya City University Graduate School of Medical Sciences (approval number: 60-25-0050) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have consented to the publication of this article.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}